RNAC Cartesian Therapeutics Inc

Price (delayed)

$7.87

Market cap

$238.11M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$5.94

Enterprise value

$154.36M

Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 18

Selecta Biosciences Inc. is a clinical stage biotechnology company leveraging its ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses. With a proven ability to induce tolerance ...

Highlights
The company's equity rose by 15% QoQ
RNAC's gross profit is up by 44% YoY but it is down by 17% QoQ
RNAC's revenue is up by 44% year-on-year but it is down by 17% since the previous quarter
The quick ratio is down by 45% YoY and by 3.6% QoQ

Key stats

What are the main financial stats of RNAC

RNAC stock price

How has the Cartesian Therapeutics stock price performed over time
Intraday
-2.6%
1 week
-0.51%
1 month
-21.61%
1 year
-19.78%
YTD
9.15%
QTD
-24.47%

Financial performance

How have Cartesian Therapeutics's revenue and profit performed over time
Revenue
$1.48M
Gross profit
$1.48M
Operating income
-$155.36M
Net income
-$151.89M
Gross margin
100%
Net margin
-10,283.8%
The company's net margin has shrunk by 191% YoY and by 20% QoQ
The operating income has shrunk by 77% YoY and by 5% QoQ
RNAC's gross profit is up by 44% YoY but it is down by 17% QoQ
RNAC's revenue is up by 44% year-on-year but it is down by 17% since the previous quarter

Price vs fundamentals

How does RNAC's price correlate with its fundamentals

Growth

What is Cartesian Therapeutics's growth rate over time

Valuation

What is Cartesian Therapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
157.01
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
104.51
The company's equity rose by 15% QoQ
RNAC's revenue is up by 44% year-on-year but it is down by 17% since the previous quarter
RNAC's P/S is 5% higher than its last 4 quarters average of 152.9

Efficiency

How efficient is Cartesian Therapeutics business performance
The company's return on sales fell by 20% QoQ
The return on assets has declined by 5% since the previous quarter
Cartesian Therapeutics's ROIC has decreased by 2.1% from the previous quarter

Dividends

What is RNAC's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for RNAC.

Financial health

How did Cartesian Therapeutics financials performed over time
Cartesian Therapeutics's total assets is 28% less than its total liabilities
The quick ratio is down by 45% YoY and by 3.6% QoQ
RNAC's current ratio is down by 44% YoY and by 2.2% QoQ
The company's debt is 151% higher than its equity
Cartesian Therapeutics's debt to equity has soared by 90% YoY
The company's equity rose by 15% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.